QRxPharma Makes Pain Connection By Teaching Old Drugs New Tricks
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Sydney-headquartered QRxPharma formed a development deal with China Aoxing Pharmaceutical for QRxPharma's lead candidate MoxDuo IV, an intravenous formulation of morphine and oxycodone for treating moderate to severe pain
You may also be interested in...
As User Fee Date Nears, Australia’s QRxPharma Moves To POC For MoxDuo CR Formulation; Secures Actavis As Partner
The company looks to position its dual-opioid combination against Purdue Pharma’s OxyContin.
Australia's QRxPharma Files NDA With U.S. FDA For Combo Opioid That Looks Safer Than Single Compounds
Sydney-headquartered QRxPharma filed in late July its MoxDuo IR (morphine/oxycodone) NDA with U.S. FDA for the treatment of moderate to severe acute pain. The NDA was submitted under the 505(b)(2) pathway, which allows for historical data because the two components of the dual opioid are already approved. Interestingly, the morphine and oxycodone combo appears to be safer than the two single compounds
Australia's QRxPharma Files NDA With U.S. FDA For Combo Opioid That Looks Safer Than Single Compounds
Sydney-headquartered QRxPharma filed in late July its MoxDuo IR (morphine/oxycodone) NDA with U.S. FDA for the treatment of moderate to severe acute pain. The NDA was submitted under the 505(b)(2) pathway, which allows for historical data because the two components of the dual opioid are already approved. Interestingly, the morphine and oxycodone combo appears to be safer than the two single compounds